Fintel reports that on April 1, 2025, William Blair upgraded their outlook for Nayax (NasdaqGS:NYAX) from Market Perform to ...

William Blair reissued their market perform rating on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research report ...

Equities researchers at William Blair issued their FY2028 earnings estimates for Tempest Therapeutics in a research report ...

William Blair analyst Margaret Kaczor maintained a Hold rating on Neuronetics (STIM – Research Report) today. The company’s shares closed ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Palantir is poised to win a U.S. Army contract that could eventually deliver annual recurring revenue approaching $100 million, said a William Blair analyst.

In a report released today, Ryan Merkel from William Blair maintained a Buy rating on Acuity Brands (AYI – Research Report). The company’s ...

Much of the attention this week for markets and economists will center on the rollout of President Donald Trump’s tariffs.

Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...

Tesla shares fell more than 5% on Wednesday, ending the EV maker's blistering rebound out of a prolonged slump.

Shares of major US drugmakers plunged Monday after reports surfaced that the FDA’s leading vaccine official was forced out as part of a shakeup at federal health agencies ordered by the ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...